Will COVID-19 Permanently Alter the Surgical Products Market? A Conversation with Tom O’Brien, Ethicon Endomechanical

article image

COVID-19 devastated elective surgery procedure volumes in the first half of 2020. Although hospitals have bounced back sooner than expected, surgical capacity remains strained. Returning to pre-pandemic levels is likely to be a multi-year challenge, according to Tom O’Brien, who says the emphasis now is on safety, efficiency, and cost-control. Ethicon is relying on real-world data to help make the case for its surgical devices.

COVID-19 has taken a toll on healthcare providers, and hospitals that rely on elective surgeries to bring in much needed revenue have been particularly hard-hit. As a result, medical device companies that supply surgical products are also feeling the pain; but some are rising to the opportunity and are taking specific measures to help their customers address the current elective surgery backlog. (See “Navigating Beyond COVID-19: What Device Companies Can Do to Survive and Thrive,” MedTech Strategist, May 21, 2020.)

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: